UNSPSC 51373325: Aspirin/caffeine/propoxyphene

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373325 Aspirin/caffeine/propoxyphene is a Commodity code that state and local governments use to classify pharmaceutical procurement, though recent solicitations show the code capturing a broader range of pharmaceutical and health-related products than the nominal name suggests. State and local issuing bodies under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multi-state and multi-jurisdictional government entities. The scope of work encompasses procurement of generic pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs supporting public health initiatives and employee group health plans.

Activity concentrates in Florida and Minnesota, with Texas involvement in preliminary market research. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026; due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent combined on administrative compliance, EDI capability, and fixed pricing; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs. These opportunities reflect state and local procurement moving toward direct contracting with manufacturers, cooperative purchasing frameworks spanning multiple jurisdictions, and integration of naloxone and harm-reduction products into standard pharmaceutical procurement channels.